Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)

• DOI: 10.1007/s00277-017-3150-3
• Publication Date: 2017-10-31T15:05:56Z
• Authors: Gabriele Nagel; D. Weber; E. Fromm; S. Erhardt; M. Lübbert; W. Fiedler; T. Kindler; J. Krauter; P. Brossart; A. Kündgen; H. R. Salih; J. Westermann; G. Wulf; B. Hertenstein; M. Wattad; K. Götze; D. Kraemer; T. Heinicke; M. Girschikofsky; H.G. Derigs; H. A. Horst; C. Rudolph; M. Heuser; G. Göhring; V. Teleanu; L. Bullinger; F. Thol; V. I. Gaidzik; P. Paschka; K. Döhner; A. Ganser; Hartmut Döhner; R. F. Schlenk
• Keywords: Adult; Aged, 80 and over; Male; Cancer Research; Adolescent; 610; Middle Aged; 3. Good health; Leukemia, Myeloid, Acute; 03 medical and health sciences; 0302 clinical medicine; fms-Like Tyrosine Kinase 3; Austria; Germany; Mutation; Humans; Original Article; Female; Registries; Aged

We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry. Adult patients with newly diagnosed AML at 63 centers in Germany and Austria were followed within the AMLSG BiO registry (NCT01252485). Between January 1, 2012, and December 31, 2014, data of 3525 patients with AML (45% women) were collected. The median age was 65 years (range 18-94). The comparison of age-specific AML incidence rates with epidemiological cancer registries revealed excellent coverage in patients < 70 years old and good coverage up to the age of 80. The distribution according to the European LeukemiaNet (ELN) risk categorization from 2010 was 20% favorable, 31% intermediate-1, 28% intermediate-2, and 21% adverse. With increasing age, the relative but not the absolute prevalence of patients with ELN favorable and intermediate-1 risk (p < 0.001), with activating FLT3 mutations (p < 0.001), with ECOG performance status < 2 (p < 0.001), and with HCT-CI comorbidity index < 3 (p < 0.001) decreased. Regarding treatment, obesity and favorable risk were associated with an intensive treatment, whereas adverse risk, higher age, and comorbidity index > 0 were associated with non-intensive treatment or best supportive care. The AMLSG BiO registry provides reliable population-based distributions of genetic, clinical, and treatment characteristics according to age.